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Abstract
In a non-selected sample of children with Neurofibromatosis type 1 (NF1) the prevalence rate of autism spectrum disorder 
(ASD) and predictive value of an observational (ADOS)—and questionnaire-based screening instrument were assessed. 
Complete data was available for 128 children. The prevalence rate for clinical ASD was 10.9%, which is clearly higher than 
in the general population. This prevalence rate is presumably more accurate than in previous studies that examined children 
with NF1 with an ASD presumption or solely based on screening instruments. The combined observational- and screening 
based classifications demonstrated the highest positive predictive value for DSM-IV diagnosis, highlighting the importance 
of using both instruments in children with NF1.
Keywords Neurofibromatosis type 1 · Autistic traits · Autism spectrum disorder · Prevalence · Autism diagnostic 
observation schedule · Social responsiveness scale
Introduction
Neurofibromatosis type 1 (NF1) is an autosomal dominant 
disorder affecting 1 in 2500–3000 individuals (Williams 
et al. 2009). The disorder is inherited in half of the cases, 
and in the other half the mutation is de novo (Messiaen et al. 
2000). The NF1 gene encodes for the protein neurofibromin, 
which activates the protein RasGTPase (Rauen 2013). Ras-
GTPase functions as a negative regulator of Ras, a protein 
involved in the regulation of the cell cycle, growth and dif-
ferentiation. As a result of mutations in NF1, a decrease 
in neurofibromin activity causes increased cell growth. 
Affected individuals are recognized by the representation 
of at least two distinctive physical features, including café-
au-lait spots, intertriginous freckling, Lisch nodules, neurofi-
bromas, optic pathway gliomas or distinctive bone-forming 
lesions (Williams et al. 2009).
Children with NF1 often experience cognitive and behav-
ioral problems (Hachon et al. 2011; Lehtonen et al. 2013). 
Generally, intelligence scores of affected children are sig-
nificantly lower compared to the general population, and 
learning problems and attention-deficit-hyperactivity dis-
order (ADHD) are common. However, the problems are 
highly variable across the NF1 population (Lehtonen et al. 
2013). Besides these common cognitive and behavioral 
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characteristics, social difficulties have been reported in chil-
dren with NF1. Children with NF1 often have poorer social 
skills, tend to be socially isolated and rejected by peers, and 
experience problems in social information processing (Bar-
ton and North 2004; Huijbregts et al. 2010; Noll et al. 2007). 
Similar to the general population, social problems in chil-
dren with NF1 are more prevalent in boys (Garg et al. 2016) 
and in children with low intellectual functioning (Huijbregts 
and De Sonneville 2011).
Recently, studies have focused on the prevalence and pro-
file of autism spectrum disorders (ASD) in children with 
NF1. Compared to global ASD prevalence estimates of 
0.8% in the general population (Baxter et al. 2015) screen-
ing-based prevalence rates of clinical ASD symptoms of 
13–29% have been found in children with NF1. On top of 
this, an additional percentage of 27–31% of children were 
found to show subclinical symptoms, leading to total esti-
mated screening-based prevalence rates of ASD symptoms 
ranging between 30–56% (Adviento et al. 2014; Constantino 
et al. 2015; Garg et al. 2013; Van Eeghen et al. 2013; Walsh 
et al. 2013). In a recent, internationally compiled sample of 
children with NF1 (N = 531), a screening-based prevalence 
rate of clinical ASD of 13% and an additional prevalence 
rate of 26% of subclinical symptoms was reported (Morris 
et al. 2016), resulting in a total prevalence rate of ASD traits 
of 39%. It should be noted, though, that these estimates are 
based on screening instruments. Because of their measure-
ment purposes, these instruments are highly sensitive and 
thus may result in a biased (slightly overestimated) ASD 
prevalence rate.
The possible overestimation of the screening-based preva-
lence rates highlights the importance of studies assessing 
clinical ASD prevalence rates. Only a few studies have 
examined clinically assessed ASD prevalence rates in chil-
dren with NF1. In the studies by Garg et al. (2013) and 
Plasschaert et al. (2015), children with a presumption of 
ASD (preselected based on elevated scores on a screening 
instrument) were assessed with clinical diagnostic instru-
ments. In these subsamples of children with NF1, ASD 
prevalence estimates of 25% (Garg et al. 2013) and 26% 
(Plasschaert et al. 2015) were reported. Because these preva-
lence rates were based on samples of children with an initial 
suspicion of autism spectrum problems, these prevalence 
rate are probably not representative for the general pediatric 
NF1 population as a whole. To our knowledge, there are 
no reports available in the literature in which an unselected 
sample of children with NF1 has been clinically assessed 
for ASD.
The primary aim of this study was to examine the 
prevalence of clinically assessed ASD in children with 
NF1 visiting a specialized NF1 outpatient clinic without 
a presumption of ASD. The secondary aim was to inves-
tigate the predictive value of a screening instrument and 
an observational assessment in relation to clinical DSM-
IV ASD diagnosis in a pediatric NF1 population. Also, the 
association of gender, age and intellectual functioning with 
ASD diagnosis was examined.
Method
Participants
Eligible for participation were children (aged 2–10) with 
either genetically or clinically diagnosed NF1. All children 
were patients of ENCORE, a multidisciplinary expertise 
center for genetic neurocognitive disorders (including NF1) 
in Rotterdam. As part of the standard multidisciplinary care 
for and follow-up of children with NF1, these children were 
routinely referred to the Department of Child and Adolescent 
Psychiatry/Psychology, between August 2011 and August 
2016. In the current study, a total of 128 children between 2 
and 10 years of age with NF1 were enrolled (45.3% female, 
mean age = 5.27, SD = 1.81).
Procedure
As standard procedure, all children underwent neuropsy-
chological evaluation and clinical assessment of autistic 
symptomatology. Additionally, parents and teachers pro-
vided information concerning the child’s development and 
the primary caregiver was asked to complete several ques-
tionnaires, including the SRS. The data in this prospective 
study was collected based on a fixed protocol in the context 
of the longitudinal follow-up for the assessment of clinical 
symptoms in children with NF1.
Measures
ASD Symptom Screening
ASD symptoms were screened with the social responsive-
ness scale (SRS) (Constantino et al. 2003). Completion of 
the 65 items by one of the parents provides information 
concerning functioning in the domains social awareness, 
social cognition, reciprocal social communication, social 
motivation, and autistic mannerisms. The total raw score, 
the sum of the 65 items, can be converted into a T-score 
(M = 50; SD = 10) using a Dutch normative reference group 
(Constantino and Gruber 2015). T-scores of 60 or higher 
indicate mild to moderate problems, and T-scores of 76 or 
more indicate severe (clinical) problems. The SRS has been 
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shown to be a valid and reliable instrument the scores are 
independent from IQ scores (Constantino et al. 2003).
Observational Assessment of ASD
Observational assessment of ASD was carried out with the 
autism diagnostic observation schedule-generic (ADOS-G) 
(Lord et al. 1999) and the autism diagnostic observation 
schedule—second edition (ADOS-2)(Lord et al. 2012). In 
most cases (i.e. 88.3%), the ADOS-2 was used. With the 
ADOS, social interaction, play and imaginative skills are 
assessed. The ADOS was performed by trained and certi-
fied psychologists. Depending on the developmental age and 
level of expressive language of the child, one of the four 
available modules of the ADOS was chosen. The ADOS 
has been shown to be a reliable and valid measure for ASD 
symptoms (Gotham et al. 2007).
ADOS-G scores were converted to ADOS-2 scores 
according to the manual (Lord et al. 2012). ASD classifi-
cations were obtained and to enable comparison between 
ASD severity across the four different modules, continuous 
calibrated severity scores (CSS) were calculated (Gotham 
et al. 2009; Hus et al. 2014; Hus and Lord 2014). The CSS 
range from zero to ten with zero indicating no or very little 
symptoms and ten indicating severe ASD symptoms.
Clinical (DSM‑IV) Diagnosis
A clinical DSM-IV diagnosis of ASD was established by a 
multidisciplinary team consisting of a child and adolescent 
psychiatrist and psychologists, combining information from 
all assessments, questionnaires, observation of the child 
and heteroanamnestic information provided by parents and 
teachers.
Intellectual Functioning
Depending on the child’s age, the level of intellectual func-
tioning was assessed with either the wechsler preschool and 
primary scale of intelligence (WPPSI-III)(Wechsler 2002) 
or the wechsler intelligence scale for children-iii (WISC-III)
(Wechsler 1991). Reliability and validity of these intelli-
gence tests have been demonstrated. Standardized verbal-, 
performance-, and full scale IQ scores were calculated 
(M = 100, SD = 15). For one child, a nonverbal intelligence 
test (i.e. the Wechsler Non Verbal scale of Ability; WNV) 
(Wechsler and Naglieri 2006) was used, for which the total 
IQ score was calculated as well. In two children, assessment 
with the Wechsler scales was not possible due to a develop-
mental delay. In these children, assessment of intellectual 
functioning was done using the Bayley Scales of Infant and 
Toddler Development third edition (Bayley 2006), and a 
developmental quotient was calculated (developmental age/
chronological age × 100, with M = 100, SD = 15).
Statistical Analyses
To study the prevalence of ASD, frequencies of the SRS 
classifications, ADOS-2 classifications, and clinically 
derived DSM-IV diagnosis were calculated. Sensitivity, 
specificity, positive predictive (PPV) and negative predic-
tive values (NPV) were calculated to assess the screening 
accuracy of the instruments’ classifications. The association 
of intelligence and age with clinically derived DSM-IV ASD 
diagnosis was examined with independent t tests. Missing 
full-scale IQ scores were imputed using mean imputation. 
The association of gender with clinically derived DSM-IV 
ASD diagnosis was examined with a Chi square test. Data 
were analyzed using IBM SPSS Statistics version 22. Results 
were considered statistically significant if the (two-tailed) 
alpha level was below .05. Sensitivity, specificity, PPV and 
NPV values were interpreted according to the guidelines 
presented by Cicchetti (2001).
Results
Sample Characteristics
Patient characteristics are summarized in Table 1. Of the 
total sample of 128 children, 58 were female (45.3%). 
The mean age at assessment of the sample was 5.27 years 
(SD = 1.81). Intelligence scores were significantly lower 
than the general population mean of 100 (SD = 15; total 
IQ t(122) = − 9.40, p < .001, verbal IQ t(123) = − 6.77, 
p < .001, performance IQ t(124) = − 9.24, p < .001). Muta-
tions in NF1 were detected as described before (Van Min-
kelen et al. 2014). The mutations were familiarly inherited in 
17.2% (N = 22) of the children and de novo in 41.4% (N = 53) 
of the children. In 41.4% of the cases it was unknown 
whether the mutation was familial or de novo, caused by 
the fact that parents were not genetically tested, one of the 
parents was not genetically tested, or the child was not genet-
ically tested yet. The SRS questionnaire was completed by 
the primary caregiver in 103 children. The mean SRS total 
T-score was 54.7 (SD = 12.60), which is significantly higher 
compared to the general population mean of 50 (SD = 10), 
t(102) = 3.79, p < .001. There were no significant differ-
ences between the group of children with and without avail-
able SRS scores regarding gender, intelligence scores, age, 
ADOS CSS or DSM-IV diagnosis.
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Autism Prevalence
Of the 128 children with NF1 included in the analyses, 14 
received a clinical DSM-IV ASD diagnosis, resulting in a 
prevalence rate of 10.9%. Based on the SRS, 8.7% of the 
patients achieved scores in the ‘severe’ (clinical) category 
(T ≥ 76) and 16.5% in the ‘mild to moderate’ category 
(T ≥ 60), leading to a total prevalence rate of 25.2%. For the 
ADOS a total percentage of 18.8% was found, with 10.2% 
of the children having an autism classification and 8.6% of 
the children met criteria for an ASD classification. These 
percentages are lower than the percentages reported earlier 
with in-depth assessments (Garg et al. 2013; Plasschaert 
et al. 2015).
Screening Accuracy
Sensitivity, specificity, positive predictive (PPV) and nega-
tive predictive values (NPV) were computed to assess the 
screening accuracy of the ADOS’ and SRS’ classifications 
in relation to a DSM-IV ASD diagnosis. The results are dis-
played in Table 2.
With an SRS total T-score cutoff of T ≥ 60 (subclinical), 
the sensitivity in relation to the DSM-IV diagnosis was 
fair (.72) and the specificity was good (.82). With a cutoff 
of T ≥ 76 (clinical), sensitivity was poor (.46) and speci-
ficity was excellent (.97). In this population of children 
with NF1, the PPV was poor (.35) when using the SRS 
cutoff of T ≥ 60, demonstrating a low probability that a 
child with NF1 with a positive (T ≥ 60) SRS score is being 
identified as having ASD according to the DSM-IV. Using 
this same cutoff of T ≥ 60, the NPV was excellent (.96), 
indicating a high probability that a child with NF1 with a 
negative score (T < 60) on the SRS is correctly identified 
as not having ASD according to the DSM-IV. Using the 
more stringent (clinical) cutoff of T ≥ 76, the PPV was 
poor (.63) and the NPV was excellent (.95).
For the ADOS classification, the sensitivity (.64) was 
poor and the specificity was good (.89). In this population 
of children with NF1, the PPV (.45) was poor, demonstrat-
ing a low probability that a child with NF1 with an ADOS 
classification is being identified as having ASD according 
to the DSM-IV. The NPV was excellent (.95), indicating a 
high probability that a child with NF1 without an ADOS 
classification is correctly identified as not having ASD 
according to the DSM-IV.
The sensitivity of the combined classification (classified 
with ASD on both the ADOS and SRS) was poor using 
both the T ≥ 60 and T ≥ 76 SRS T-score cutoffs (.46 and 
.27, respectively). The specificity for both combined clas-
sifications was excellent (.98 and .99, respectively). In this 
population of children with NF1, for both combined clas-
sifications the PPV was fair (.71 and .75, respectively) and 
the NPV was excellent (.93 and .91, respectively).
In order to explain the finding of the substantially 
increased PPV when using the combined classification, 
an in-depth examination of the distribution of ADOS and 
SRS scores was performed. The number of participants 
with an SRS classification (for both T ≥ 60 and T ≥ 76) 
and ADOS classification were compared to the number 
Table 1  Patient characteristics
N (%) Mean (SD) Min Max
Age at assessment (years) 128 5.27 (1.81) 2 10
Female gender 58 (45.3%)
Mutation
 Familial 22 (17.2%)
 De novo 53 (41.4%)
 Unknown 53 (41.4%)
ADOS modules
 Module 1 12 (9.4%)
 Module 2 45 (35.2%)
 Module 3 71 (55.5%)
ADOS calibrated severity 
score
 Total 128 2.34 (1.83) 1 8
 Social affect 128 2.70 (2.12) 1 9
 Restricted/repetitive 
behaviors
128 3.34 (2.50) 1 10
Type of intelligence test
 WPPSI 98 (76.5%)
 WISC-III 27 (21.1%)
 WNV-III 1 (.8%)
 BSID-III 2 (1.6%)
IQ scores
 Full-scale IQ 123 88.20 (13.93) 55 119
 Verbal IQ 124 91.64 (13.75) 57 124
 Performance IQ 125 88.25 (14.21) 58 130
SRS
 Total T-score 103 54.70 (12.59) 35 103
Table 2  Sensitivity, specificity, positive predictive value (PPV) 
and negative predictive value (NPV) of the SRS parental report and 
ADOS classification compared to DSM-IV classification
Sensitivity Specificity PPV NPV
SRS class. T ≥ 60 .72 .82 .35 .96
SRS class. T ≥ 76 .46 .97 .63 .95
ADOS class .64 .89 .45 .95
ADOS class. + SRS class. 
T ≥ 60
.46 .98 .71 .93
ADOS class. + SRS class. 
T ≥ 76
.27 .99 .75 .91
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of participants with a classification on both instruments. 
The results are displayed in Table 3. As can be seen, the 
percentage of classification agreement is low for both the 
ADOS and SRS T ≥ 60 and the ADOS and SRS T ≥ 76 
(i.e. 8.7% and 4.9%). Figure 1 demonstrates that the SRS 
and ADOS both classify and fail to classify unique cases: 
a number of children with a SRS score of T ≥ 60 or T ≥ 76 
are classified by the ADOS as ‘non-spectrum’ and a num-
ber of children with an ADOS ASD classification had a 
SRS T-score below 60.
Correlates
There were no significant differences in full-scale, verbal, 
and performance intelligence scores between the group 
of children with and without DSM-IV ASD diagnosis 
(Table 2). Significantly more boys (N = 11) were clinically 
diagnosed with ASD according to the DSM-IV criteria com-
pared to girls (N = 3). The group of children with a clinical 
ASD diagnosis was significantly older (mean age = 6.36) 
compared to the group without diagnosis (mean age = 5.13) 
(Table 4).
Discussion
The present study aimed to examine the prevalence of ASD 
in a sample of children with NF1 without a presumption 
of autistic symptoms. In our cohort of children with NF1, 
Table 3  Percentage agreement in ASD classifications between ADOS 
and SRS
ADOS
Yes No
SRS T ≥ 60
 Yes 8.7% (9/103) 16.5% (17/103)
 No 8.7% (9/103) 66.0% (68/103)
SRS T ≥ 76
 Yes 4.9% (5/103) 3.9% (4/103)
 No 12.6% (13/103) 78.6% (81/103)
Fig. 1  Scatterplot illustrating 
the distribution of SRS total 
T-scores (dotted lines indicate 
the SRS total cutoff scores 
T ≥ 60 and T ≥ 76) for the two 
ADOS categories (non-spec-
trum and ASD), demonstrating 
low agreement between the 
instruments
Table 4  Correlates DSM-IV diagnosis
t df p χ2 p
Gender – – – 4.05 .044
Full-scale IQ 1.09 111 .28 – –
Verbal IQ .62 112 .53 – –
Performance IQ 1.33 113 .19 – –
Age − 2.36 116 .02 – –
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we found a DSM-IV based ASD prevalence rate of 10.9%. 
Secondly, we aimed to assess the predictive value of a 
screening-based and observational instrument on the clinical 
DSM-IV ASD diagnosis. In this population of children with 
NF1, combining the classifications from both instruments 
yielded the highest predictive value on DSM-IV diagnosis. 
Thirdly, we examined several possible correlates and found 
a significant effect of gender and age on DSM-IV ASD diag-
nosis. Our reported DSM-IV based ASD prevalence rate of 
10.9% endorses previous reports of an increased prevalence 
rate in children with NF1 as compared to the general popu-
lation prevalence of about 0.8% (Baxter et al. 2015), and 
confirms the involvement of the various mutations leading to 
NF1 in the development of ASD (Morris et al. 2016). To our 
knowledge, this is the first study in which ASD prevalence is 
assessed in a sample of children with NF1 without an initial 
presumption of ASD. The prevalence reported in this study 
is likely more representative and accurate for the general 
pediatric NF1 population than reported by previous studies 
(Garg et al. 2013; Plasschaert et al. 2015).
Earlier reports of ASD prevalence rates have reported 
screening-based prevalence rates from 13 to 33% (Adviento 
et al. 2014; Constantino et al. 2015; Garg et al. 2013; Van 
Eeghen et al. 2013; Walsh et al. 2013) and prevalence rates 
based on a observational instrument of 25–26% (Garg et al. 
2013; Plasschaert et al. 2015). The results from the obser-
vational- and screening instrument demonstrate that not 
all children with a classification on one of the instruments 
receive an eventual DSM-IV diagnosis. This implies that a 
group of children is present with subclinical ASD symptoms 
in the sample studied here. The percentage of children with 
screening-based subclinical ASD symptoms (i.e. 16.5%) 
found in this study supports this. The question for future 
research remains whether this group of children with NF1 
with subclinical ASD symptoms will receive a DSM-IV 
ASD diagnosis at a later age.
The substantial increase in PPV for the combination 
of the instruments’ classification scores demonstrates the 
complementing effect of the two instruments in predicting 
DSM-IV ASD diagnosis. This might be explained by the 
difference in the assessment methods (e.g. informant and 
situation) of the instruments. In case of the SRS, one of the 
primary caregivers of the child acts as informant for ASD 
symptoms, whereas in case of the ADOS a trained and certi-
fied clinician observes and scores the behavior of the child. 
Different informants provide valuable and unique informa-
tion with regard to ASD symptomatology, due to discrepan-
cies in perspective and context, as demonstrated by Duvekot 
et al. (2015). Moreover, the ADOS assessment is performed 
in a semi-structured observational lab-setting, whereas the 
SRS assesses the child’s behavior in daily life. The instru-
ments provide unique information concerning autistic symp-
toms in the child; the classification agreement between the 
instruments is low (Table 3) and both instruments classify 
and fail to classify unique cases (Fig. 1). This underlines the 
importance of combining the findings from both instruments 
for ASD assessment in clinical practice.
The group of children with a DSM-IV ASD diagnosis was 
significantly older compared to the group without diagnosis. 
It has been demonstrated that children with ASD and other 
developmental, psychiatric, or neurologic comorbidities are 
usually diagnosed with ASD at a later age, possibly because 
the ASD symptoms are ‘masked’ by the comorbidities (Levy 
et al. 2010) or because assessment and treatment of somatic 
complaints are prioritized. As a consequence, our sample of 
children with NF1 might receive a DSM-IV ASD diagnosis 
at a later age or receive subclinical scores.
Intelligence scores were not related to the DSM-IV ASD 
diagnosis. This could be due to the lack of dispersion in 
intelligence scores in our sample, resulting in a homoge-
nous sample regarding cognitive functioning. Examination 
of gender effects demonstrated an increased number of boys 
with a DSM-IV ASD diagnosis. This result is in line with 
the male predominance of ASD in the general population 
and the presumed female protective effect (Halladay et al. 
2015) and with reports of higher prevalence rates of ASD 
in boys with NF1 (Garg et al. 2016).
A limitation in the current study is that SRS was not 
available in all children in this study. The parental response 
rate of 80% might have provided skewed results, since the 
exact reason for not completing the SRS questionnaire is 
unknown. However, there were no significant differences 
between the group of children from responders and non-
responders regarding gender, intelligence scores, age, DSM-
IV ASD diagnosis or ADOS total CSS, ADOS social affect 
CSS and ADOS restricted/repetitive behaviors CSS, thus 
it seems unlikely that differences in SRS scores between 
responders and non-responders would have been present. 
Secondly, the combination of the ADOS and ADI-R are gen-
erally advocated in ASD research, but the ADI-R was not 
included in the current study. The data in the current study 
was initially collected for patient care and the implementa-
tion of the ADI-R would have been too time-consuming. 
Instead, a thorough intake and heteroanamnestic interview 
with the parents was conducted. Thirdly, the sample used 
in this study included a number of two- and three year old 
children and ASD is often diagnosed at a later age. However, 
the instruments used in the current study are valid instru-
ments for the assessment of autism and autism spectrum 
disorders in young children. Fourthly, since the data was col-
lected from 2011 onwards, the ASD diagnoses were DSM-
IV based instead of DSM-V. Finally, although all children 
within ENCORE with NF1 were referred to the Department 
of Child and Adolescent Psychiatry/Psychology for neu-
ropsychological evaluation and assessment of autistic symp-
tomatology, a clinical referral bias might still be present in 
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our sample. The problems experienced in children with NF1 
are highly variable, and the severities of the difficulties fluc-
tuate across the population (Lehtonen et al. 2013). Parents 
of children with for example more severe physical difficul-
ties or developmental delays might shift their focus to these 
more pressing problems and postpone neuropsychological 
and behavioral assessment. At the same time, parents of chil-
dren who experience limited to no difficulties might not see 
the need for neuropsychological or behavioral assessment. 
Nevertheless, the sample studied here is a key strength of the 
study; to our knowledge, this is the first study in which an 
unselected cohort of children with NF1 is referred for assess-
ment of autistic symptomatology, regardless of an ASD pre-
sumption. The relatively large sample size of children with 
NF1 further strengthens our results. All children underwent 
uniform neuropsychological and ASD assessments, enabling 
unique comparisons between different instruments for ASD 
symptoms and comparison with the eventual DSM-IV ASD 
diagnosis, as well as the examination of potential correlates 
with the diagnosis.
Conclusion
A DSM-IV ASD prevalence rate of 10.9% demonstrates that 
the prevalence of ASD symptoms in children with NF1 is 
considerably higher compared to the general population, 
hereby emphasizing the importance of ASD assessment in 
this population. Our results underline the relevance of the 
use of multiple instruments (screening- and observational) 
for clinicians in order to correctly identify as many individu-
als with NF1 with ASD as needed. In addition to the group 
of children with a diagnosis, a substantial group of children 
with subclinical ASD symptoms is present as well, as was 
demonstrated by the screening- and observational instru-
ment. This demonstrates the necessity to structurally follow 
the development of children with NF1.
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